Suppr超能文献

供体特异性输血导致对同种异体次要抗原低反应性的机制。

Mechanism of hyporesponsiveness caused by donor-specific transfusion to allogeneic minor antigens.

作者信息

Nomoto K, Kanoh K, Suzuki H, Shimura T, Kuwano H

机构信息

First Department of Surgery, Gunma University, Maebashi, Japan.

出版信息

Eur Surg Res. 2001 May-Jun;33(3):217-24. doi: 10.1159/000049709.

Abstract

Donor-specific transfusion (DST) is one of the methods to prevent allograft rejection, presumably through induction of donor-specific nonresponsiveness in humans and animal models. In this study, we used a skin graft model in fully allogeneic (AKR into B6), H-2 class I-disparate (bm1 into B6), class II-disparate (bm12 into B6), minor-H-disparate (C3H/SW into B6) and whole MHC-disparate (B10.BR into B10) combinations to analyze the mechanisms of DST-induced immunomodulation from the view point of antigen disparity. Skin graft survival was prolonged by DST only in the combination of bm1 and B6 as already confirmed by many reports. In other combinations, skin graft survivals were not prolonged at all by DST but rather shortened. In a fully allogeneic combination between AKR and B6 in which I-E antigens or Mls-1 antigens are recognized by T-cell subsets with TCR Vbeta11 or Vbeta6, respectively, responses to stimulation by anti-Vbeta11 and Vbeta6 monoclonal antibodies were decreased by DST. Furthermore, the number of Vbeta6+ T cells was decreased in the periphery probably due to peripheral clonal deletion. In such a condition, the mixed lymphocyte reactions of B6 to AKR were reduced to some extent, but were clearly detected. In addition, skin allografts from AKR were more rapidly rejected in B6 mice given AKR spleen cells. From these results, DST seems to induce nonresponsiveness to some antigens (I-E antigens, Mls antigens and bm1 antigens in this study), but not to others. Our study also indicated that DST alone, at least in the absence of other treatments, does not contribute to allograft tolerance in fully allogeneic combinations.

摘要

供者特异性输血(DST)是预防同种异体移植排斥反应的方法之一,据推测,它是通过在人类和动物模型中诱导供者特异性无反应性来实现的。在本研究中,我们使用了完全同种异体(AKR到B6)、H-2 I类不相合(bm1到B6)、II类不相合(bm12到B6)、次要组织相容性抗原不相合(C3H/SW到B6)以及整个主要组织相容性复合体不相合(B10.BR到B10)的皮肤移植模型,从抗原差异的角度分析DST诱导免疫调节的机制。正如许多报道已经证实的那样,只有在bm1和B6的组合中,DST才能延长皮肤移植的存活时间。在其他组合中,DST根本不会延长皮肤移植的存活时间,反而会缩短。在AKR和B6之间的完全同种异体组合中,I-E抗原或Mls-1抗原分别被带有TCR Vβ11或Vβ6的T细胞亚群识别,DST可降低对抗Vβ11和Vβ6单克隆抗体刺激的反应。此外,外周血中Vβ6+ T细胞的数量可能由于外周克隆清除而减少。在这种情况下,B6对AKR的混合淋巴细胞反应在一定程度上降低,但仍能明显检测到。此外,在给予AKR脾细胞细胞的B6小鼠中,来自AKR的皮肤同种异体移植被更快地排斥。从这些结果来看,DST似乎能诱导对某些抗原(本研究中的I-E抗原、Mls抗原和bm1抗原)产生无反应性,但对其他抗原则不然。我们的研究还表明,至少在没有其他治疗的情况下,单独的DST对完全同种异体组合中的移植耐受没有作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验